SK Biopharmaceuticals Co., Ltd. (326030.KS)
KRW 103600.0
(-2.54%)
KRW 103600.0
(-2.54%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -32.88 Billion KRW | 76.42% |
| 2022 | -139.43 Billion KRW | -315.02% |
| 2021 | 64.84 Billion KRW | 126.21% |
| 2020 | -247.41 Billion KRW | -245.94% |
| 2019 | -71.51 Billion KRW | 48.21% |
| 2018 | -138.09 Billion KRW | -41.42% |
| 2017 | -97.64 Billion KRW | -221.63% |
| 2016 | -30.36 Billion KRW | -8.2% |
| 2015 | -28.06 Billion KRW | 24.26% |
| 2014 | -37.04 Billion KRW | 9.64% |
| 2013 | -41 Billion KRW | -35.18% |
| 2012 | -30.33 Billion KRW | -55.82% |
| 2011 | -19.46 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 28.13 Billion KRW | 119.26% |
| 2024 Q1 | 12.83 Billion KRW | 89.83% |
| 2023 Q1 | -2.36 Billion KRW | 94.6% |
| 2023 Q3 | -13.93 Billion KRW | 40.32% |
| 2023 Q2 | -23.34 Billion KRW | -885.44% |
| 2023 FY | -32.88 Billion KRW | 76.42% |
| 2023 Q4 | 6.75 Billion KRW | 148.52% |
| 2022 FY | -139.43 Billion KRW | -315.02% |
| 2022 Q4 | -43.85 Billion KRW | -193.13% |
| 2022 Q3 | -14.96 Billion KRW | 67.05% |
| 2022 Q2 | -45.4 Billion KRW | -28.97% |
| 2022 Q1 | -35.2 Billion KRW | -174.7% |
| 2021 FY | 64.84 Billion KRW | 126.21% |
| 2021 Q4 | 47.12 Billion KRW | 206.44% |
| 2021 Q2 | -66.99 Billion KRW | -151.94% |
| 2021 Q3 | -44.27 Billion KRW | 33.92% |
| 2021 Q1 | 128.99 Billion KRW | 321.96% |
| 2020 FY | -247.41 Billion KRW | -245.94% |
| 2020 Q4 | -58.11 Billion KRW | 7.86% |
| 2020 Q2 | -59.62 Billion KRW | 10.46% |
| 2020 Q1 | -66.59 Billion KRW | -25.49% |
| 2020 Q3 | -63.07 Billion KRW | -5.78% |
| 2019 Q4 | -53.06 Billion KRW | -5.62% |
| 2019 FY | -71.51 Billion KRW | 48.21% |
| 2019 Q3 | -50.24 Billion KRW | -17.84% |
| 2019 Q2 | -42.63 Billion KRW | -159.14% |
| 2019 Q1 | 72.1 Billion KRW | 0.0% |
| 2018 FY | -138.09 Billion KRW | -41.42% |
| 2017 FY | -97.64 Billion KRW | -221.63% |
| 2016 FY | -30.36 Billion KRW | -8.2% |
| 2015 FY | -28.06 Billion KRW | 24.26% |
| 2014 FY | -37.04 Billion KRW | 9.64% |
| 2013 FY | -41 Billion KRW | -35.18% |
| 2012 FY | -30.33 Billion KRW | -55.82% |
| 2011 FY | -19.46 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 12.87 Billion KRW | 355.479% |
| Green Cross Holdings Corporation | -54.13 Billion KRW | 39.259% |
| Green Cross Holdings Corporation | -26.63 Billion KRW | -23.472% |
| Pharmicell Co., Ltd. | 3.57 Billion KRW | 1019.033% |
| Green Cross Corporation | -26.63 Billion KRW | -23.472% |
| GeneOne Life Science, Inc. | -77.76 Billion KRW | 57.717% |
| Celltrion, Inc. | 535.64 Billion KRW | 106.139% |
| Samsung Biologics Co.,Ltd. | 857.69 Billion KRW | 103.834% |
| SK bioscience Co.,Ltd. | 22.31 Billion KRW | 247.34% |
| Prestige BioPharma Limited | -32.92 Billion KRW | 0.117% |